Skip to main content

Briefing: Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says

Strategic angle: Eli Lilly's CEO expresses opposition to the White House's efforts to codify drug pricing reforms.

by Editorial Staff|Apr 1, 2026|1 MIN READ|WORLD

Eli Lilly's CEO Dave Ricks spoke with CNBC.

The company opposes the 'most favored nation' drug pricing proposal.

The push is part of a broader effort by the White House.